Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion.
- 1Department of Pharmacy, School of Medicine & Health Sciences, Wuxi Taihu University, Wuxi, Jiangsu Province, People's Republic of China.
Abstract
Adoptive antitumor immunity ultimately fails because metabolically hostile tumor microenvironments (TME) drive T cells into a dysfunctional exhausted state that current checkpoint blockade only partially reverses. Crucially, the principal metabolic stresses - accumulation of lactate, lipids and adenosine, deprivation of glucose and amino acids, and hypoxia - do not act in isolation but form a densely cross-regulated network that progressively reinforces T cell exhaustion. This review synthesizes how each barrier arises and how they amplify one another, then maps nanomaterial-based countermeasures onto this network: catalytic nanomaterials that degrade lactate and adenosine, lipid-modulating and mitochondria-targeted formulations, amino-acid replenishment systems, and hypoxia-relieving designs that pair metabolic correction with checkpoint inhibition or photodynamic therapy. Particular attention is given to the design principles - tissue targeting, stimuli-responsive release and rational combination - that determine whether metabolic reprogramming yields durable restoration of T cell function rather than transient phenotypic rescue. Emerging preclinical evidence indicates that nanomaterial-mediated metabolic remodeling can convert the immunosuppressive TME into an immune-supportive niche and recover effector function of exhausted T cells. We further identify the key gaps that currently limit clinical translation: the absence of subset-level evaluation distinguishing reversible progenitor-like exhausted T cells from terminally exhausted cells, the lack of epigenetic endpoints such as histone lactylation, off-target metabolic suppression of T cells themselves, and the manufacturing and safety hurdles of clinical-grade nanomaterials. Resolving these issues would establish metabolic reprogramming as a credible frontier for next-generation cancer immunotherapy.
Related
- Exercise oncology and tumor sterol metabolism: An emerging mechanistic frontier
- Targeting lipid metabolism to overcome therapeutic resistance in renal cell carcinoma: Mechanisms and emerging strategies.
- Extract from Eucommia ulmoides Oliv. Leaves alleviates APAP-induced acute liver injury via reshaping gut microbiota and attenuating microbial bile acids metabolism disorder.
- Targeting cholesterol metabolism to overcome Zanubrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma
- The new frontier of newborn screening: integrating genomics, metabolomics, and data science for inborn errors of metabolism
BibTeX
@article{zhu2026nanomaterials,
title = {{Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion.}},
author = {Xiaoyan Zhu and Lin He and Jinwei Li and Shuhui Guo and Xiaoxin Liu and Yongjing Cao and Shaozheng Song},
journal = {International journal of nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s639887},
url = {https://europepmc.org/article/MED/42903895},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion.
AU - Xiaoyan Zhu
AU - Lin He
AU - Jinwei Li
AU - Shuhui Guo
AU - Xiaoxin Liu
AU - Yongjing Cao
AU - Shaozheng Song
PY - 2026
DA - 2026/10/16
JO - International journal of nanomedicine
DO - 10.2147/ijn.s639887
UR - https://europepmc.org/article/MED/42903895
AB - Adoptive antitumor immunity ultimately fails because metabolically hostile tumor microenvironments (TME) drive T cells into a dysfunctional exhausted state that current checkpoint blockade only partially reverses. Crucially, the principal metabolic stresses - accumulation of lactate, lipids and adenosine, deprivation of glucose and amino acids, and hypoxia - do not act in isolation but form a densely cross-regulated network that progressively reinforces T cell exhaustion. This review synthesizes how each barrier arises and how they amplify one another, then maps nanomaterial-based countermeasures onto this network: catalytic nanomaterials that degrade lactate and adenosine, lipid-modulating and mitochondria-targeted formulations, amino-acid replenishment systems, and hypoxia-relieving designs that pair metabolic correction with checkpoint inhibition or photodynamic therapy. Particular attention is given to the design principles - tissue targeting, stimuli-responsive release and rational combination - that determine whether metabolic reprogramming yields durable restoration of T cell function rather than transient phenotypic rescue. Emerging preclinical evidence indicates that nanomaterial-mediated metabolic remodeling can convert the immunosuppressive TME into an immune-supportive niche and recover effector function of exhausted T cells. We further identify the key gaps that currently limit clinical translation: the absence of subset-level evaluation distinguishing reversible progenitor-like exhausted T cells from terminally exhausted cells, the lack of epigenetic endpoints such as histone lactylation, off-target metabolic suppression of T cells themselves, and the manufacturing and safety hurdles of clinical-grade nanomaterials. Resolving these issues would establish metabolic reprogramming as a credible frontier for next-generation cancer immunotherapy.
SN - 1176-9114
SN - 1178-2013
ER -